This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.

Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening form of pulmonary hypertension, caused by obstruction of the large and/or medium pulmonary arteries by organized thrombi. Currently, a multimodal approach, including surgical and endovascular treatment, using modern specific drugs has improved treatment results. This clinical case demonstrates the successful treatment with triple PAH-specific therapy and balloon angioplasty of the pulmonary arteries in the patient with severe CTEPH associated with systemic lupus erythematosus and antiphospholipid syndrome.

Relevance. Arterial hypertension (AH) is a significant risk factor for cardiovascular diseases. Despite advancements in the diagnosis and treatment of AH, the level of knowledge among physicians and students remains insufficient, necessitating further study.
The aim of the study. To assess awareness of doctors and senior medical students regarding the definition, classification and diagnosis of arterial hypertension.
Materials and Methods. Data from the second phase of the PHYSTARH project (2019-2023) were analyzed – anonymous surveys of 494 physicians from 10 regions of Russian Federation and 426 students from 10 universities in Russian Federation and Kyrgyzstan. The questionnaire was based on clinical guidelines. The results were compared with data from 2017–2019. Statistical methods and tests used included the Kolmogorov-Smirnov test, Mann-Whitney U test, Kruskal-Wallis test, Pearson correlation, median test for independent samples, ANOVA modeling, and regression scatter plot analysis. Differences were considered significant at p-values <0.05.
Results. The overall level of knowledge proved to be insufficient. The average level of correctness (completeness) of answers (LCA) was 58.4% for students and 62.4% for physicians (compared to 49.4% and 55.3% in 2017-2019, respectively). The worst results were obtained in questions about home blood pressure monitoring and the definition of resistant, masked, and isolated ambulatory hypertension.
Conclusion. The knowledge of students and physicians regarding key aspects of arterial hypertension requires improvement. Additional educational programs are essential.

Aim. To assess the impact of obstructive sleep apnea (OSA) on renal function in young and middle-aged men with stage 1 hypertension.
Materials and methods. A single-center, cross-sectional study included 99 men aged 18–59 years. All patients had such tests, as: office blood pressure (BP) measurement, 24-hour BP monitoring, sleep-disordered breathing testing, and renal function assessment using estimated glomerular filtration rate (eGFR, CKD- EPI formula) and microalbuminuria (MAU).
Results. OSA was detected in 67% of patients (median apnea/hypopnea index (AHI) – 20.05 events/hour). In the group with AHI ≥15 events/h compared with the group with AHI <15 events/h, the eGFR was lower (63.94 [55.95; 85.11] vs. 86.33 [80.11; 94.36] ml/min/1.73 m²; p<0.01), and the MAU value was higher (17.75 [6.90; 35.30] vs. 5.40 [0.30; 13.90] mg/day; p<0.001); the percentage of patients with MAU >30 mg/day was 25.9% vs. 6.7%, respectively (p=0.029). BP levels did not differ significantly between the groups. eGFR correlated negatively with AHI (ρ=−0.33, p=0.001) and positively with mean SpO₂ (ρ=0.41; p<0.001); MAU correlated positively with AHI (ρ=0.29; p=0.004) and negatively with mean SpO₂ (ρ=−0.40; p<0.001). There were predicted a high risk of eGFR decreasing ≤79.43 μmol/L (AUC=0.66±0.06; p<0.00) and a risk of the presence of MAU higher than 17 mg/day (AUC=0.70±0.05; p<0.00) in the group with AHI ≥15 events/h. In a multivariate logistic regression that included age, AHI and BMI, age and AHI were independent markers of decreased renal function (OR 0.92; 95% CI 0.88–0.97; p<0.00; and OR 0.98; 95% CI 0.96–0.99; p=0.03, respectively), while BMI had no significant effect.
Conclusion. In male patients with stage I hypertension, the presence of OSA is associated with worsening renal function (decreased eGFR, increased MAU), which emphasizes the necessity for OSA screening and inclusion its correction in the nephroprotective strategy; prospective studies are needed to clarify the effect of OSA therapy on renal outcomes.

On May 23, 2025, an expert council was held to discuss the place of a fixed combination of valsartan and indapamide Valsacor® INDA in the treatment of patients with arterial hypertension in various clinical situations – in patients with diabetes mellitus and metabolic disorders, the elderly, the ones with high cardiovascular risk, target organ damage (left ventricular hypertrophy, chronic kidney disease, cognitive impairment).